Roche to Buy InterMune for $8.3B, Adds Lung Drug

Aug. 25 (Bloomberg) -- Roche is strengthening its portfolio of medicines for respiratory ailments with an agreement to buy InterMune for $8.3 billion in cash. Olivia Sterns reports on “In The Loop.” (Source: Bloomberg)
A Nuclear Deal for Iran
54:41 - Bottom Line's Encore segment, a recap this weeks top stories. (Source: Bloomberg)
  • How Will Apple Impact the Dow?
  • Will Stocks Continue to Selloff on Jobs Report?
  • The Apple Effect: Does Being Added to the Dow Matter?